Donate For Public and Patients Store Search

F095 - Translating Evidence into Practice: Atopic Dermatitis Guidelines

Sunday, March 3; 1:00 PM - 3:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Discuss recent literature on AD co-morbidities
  • Analyze placement of newer therapeutic alternatives into the therapeutic algorithm
  • Describe evolution of 2014 AD Guidelines in relationship to newer literature

Description

This session will update learners on recent developments in atopic dermatitis. Areas of emphasis will include co-morbidities, therapeutic advances, and important developments subsequent to the publication of the 2014 AD Management Guidelines.

Disclosures

  • Eichenfield, Lawrence F., MD: Abbvie – I(Grants/Research Funding); Almirall – C(H); Anacor Pharmaceuticals, Inc. – C(H); Asana BioSciences – Data Safety Monitoring Board(H); Cutanea Life Sciences – C(H); Dermavant Sciences, Inc. – C(H); Dermira – C(H); Dr. Reddy – C(H); DS Laboratories – C(H); Elsevier Inc. – O(IP); Forte – A(H); Galderma Laboratories, L.P. – C(H), I(Fees); Glenmark Pharmaceuticals, Inc. – Data Safety Monitoring Board(H); LEO Pharma, US – C(H), I(Fees); Lilly ICOS LLC – C(H); MatriSys Bioscience – C(H); Medimetriks Pharmaceuticals, Inc. – C(H); Novan – C(H); Pfizer Inc. – C(H), I(Grants/Research Funding); Sanofi/Regeneron – C(H), I(Fees); TopMD – C(SO); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Fees); Verrica Pharmaceuticals Inc – A(SO), C(H), I(Grants/Research Funding); Wiley-Blackwell – O(H);
  • Paller, Amy S., MD: AbbVie – I(NC); Amgen – C(H), I(NC); Amicus Therapeutics – C(H); Boehringer Ingelheim – C(H); BridgeBio Pharma, LLC – A(H), C(H); Castle Creek Pharmaceuticals – C(H); Celgene Corporation – I(NC); Chameleon Communications – C(H); Dermavant Sciences – C(H); Dermira – C(H); Eli Lilly and Company – C(H); Expanscience – Speaker/Faculty Education(H); Forte Biosciences – C(H); Galderma Laboratories, L.P. – C(H); Janssen Pharmaceuticals, Inc – I(NC); Leo Pharma Inc – I(Grants/Research Funding); Menlo Therapeutics – A(H), C(H); MorphoSys AG – C(H); Novartis Pharmaceuticals Corp. – C(H); Pfizer Inc. – C(H); Regeneron – C(H); Sanofi/Regeneron – A(H); Stiefel a GSK company – C(H); TARGET Pharma – C(H); Theravance Biopharma – C(H); Union Therapeutics – C(H); Valeant Pharmaceuticals North America LLC – C(H); Verrica Pharmaceuticals Inc – C(H);
  • Sidbury, Robert, MD, MPH: Brickell Biotech, Inc. – I(Grants/Research Funding); Galderma Global – SP(H); Galderma USA – I(Grants/Research Funding); Micreos – C(NC); Pfizer Inc. – A(H); Regeneron Pharmaceuticals, Inc. – I(NC);
  • Simpson, Eric Lawrence, MD: AbbVie – C(Fees), I(Grants/Research Funding); Boehringer Ingelheim – C(Fees); Demira – C(Fees); Dermavant Sciences – C(Fees); Eli Lilly and Company – C(Fees), I(Grants/Research Funding); Forte Biosciences – C(Fees); Galderma Laboratories, LP – I(Grants/Research Funding); Incyte Corporation – C(Fees); Kyowa Hakko Kirin Pharma, Inc. – I(Grants/Research Funding); Leo Pharma Inc. – C(Fees), I(Grants/Research Funding); Menlo Therapeutics Inc. – C(Fees); Merck – I(Grants/Research Funding); Pfizer Inc. – C(Fees), I(Grants/Research Funding); Pierre Fabre Dermo Cosmetique France – C(Fees); Regeneron – C(Fees), I(Grants/Research Funding); Sanofi Genzyme – C(Fees); Valeant Pharmaceuticals International – C(Fees);
Schedule
Sunday, March 3
1:00 PM
Dr. Sidbury / Introduction
1:05 PM
Dr. Simpson / Update on Co-morbidities
1:30 PM
Dr. Simpson / Q & A with Dr. Simpson
1:35 PM
Dr. Sidbury / AD Potpourri
1:55 PM
Dr. Sidbury / Q & A with Dr. Sidbury
2:00 PM
Dr. Eichenfield / Guideline Update
2:25 PM
Dr. Eichenfield / Q & A with Dr. Eichenfield
2:30 PM
Dr. Paller / Update on Therapy
2:55 PM
Dr. Paller / Q & A with Dr. Paller
Event Details
  • Date
    Sunday, March 3
  • Time
    1:00 PM - 3:00 PM
  • Location
    Ballroom A
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Robert Sidbury, MD, MPH, FAAD
Speakers
  • Amy S. Paller, MD, FAAD - Handout
  • Eric Lawrence Simpson, MD, FAAD
  • Lawrence F. Eichenfield, MD, FAAD